

# Lexagene Hldgs Inc.

14:48 08 Aug 2019

## LexaGene to beta test its rapid pathogen detector at Assurance Scientific Laboratories

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) is teaming up with Assurance Scientific Laboratories (ASL) to test its rapid pathogen detection technology on urine samples.

The company announced an agreement Thursday to place a beta prototype of its LX Analyzer at ASL's facility in Vestavia, Alabama, which, among other things, tests more than 300 urine samples per week for urinary tract infections (UTIs).

The beta test will focus on detecting pathogens which cause the infections while also screening for genetic markers of antimicrobial resistance — the resistance of bacteria, fungus and viruses to drugs.

**READ:** LexaGene receives high-level approval from CDC and FDA to test pathogen samples

During the tests, ASL will use the LX Analyzer's open access feature to compare its pathogen detection and antimicrobial resistance characterization technology to ASL's own. The goal is to help clinical laboratories assess the available tools for diagnosing and treating UTIs.

"This collaborative effort with ASL, a reference laboratory that processes human samples for clinical diagnostic testing, is a perfect example of a laboratory taking advantage of the open-access feature to test the performance of their own assays on our fully automated analyzer," CEO Jack Regan said in a statement.

"We are excited to have this opportunity to demonstrate the instrument's capabilities, and how it may someday be used for human clinical diagnostics."

The company's share edged 4.4% lower Thursday to C\$0.66 on the Venture in Toronto and 3.6% to US\$0.50 on OTC Markets.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security,

**Price:** 0.69

**Market Cap:** \$59.1 m

### 1 Year Share Price Graph



January 2019 July 2019 January 2020

### Share Information

**Code:** LXG

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>0.93</b>	<b>0.45</b>

**Sector:** Medical technology & services

**Website:** [www.lexagene.com](http://www.lexagene.com)

### Company Synopsis:

*LexaGene is a biotechnology company developing a fully automated pathogen detection platform for use at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexagene Hldgs Inc. named herein, including the promotion by the Company of Lexagene Hldgs Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).